0001171843-23-006794.txt : 20231107 0001171843-23-006794.hdr.sgml : 20231107 20231107070039 ACCESSION NUMBER: 0001171843-23-006794 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231107 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231107 DATE AS OF CHANGE: 20231107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HARVARD BIOSCIENCE INC CENTRAL INDEX KEY: 0001123494 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 043306140 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33957 FILM NUMBER: 231381493 BUSINESS ADDRESS: STREET 1: 84 OCTOBER HILL RD CITY: HOLLISTON STATE: MA ZIP: 01746 BUSINESS PHONE: 5088938999 MAIL ADDRESS: STREET 1: 84 OCTOBER HILL ROAD CITY: HOLLISTON STATE: MA ZIP: 01746 8-K 1 f8k_110323.htm FORM 8-K
0001123494 false 0001123494 2023-11-07 2023-11-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 7, 2023

 

 

 

HARVARD BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

 

 

  

 

Delaware 001-33957 04-3306140
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

84 October Hill Road

Holliston, MA 01746

(Address of Principal Executive Offices) (Zip Code)

 

(508) 893-8999

(Registrant's telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:    
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value HBIO The NASDAQ Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 7, 2023, Harvard Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the three and nine months ended September 30, 2023, and the details of a related conference call to be held at 8:00 AM ET on November 7, 2023. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.

 

The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number Description
   
99.1 Press Release issued by Harvard Bioscience, Inc. on November 7, 2023
104 Cover Page Interactive Data File (embedded within the XBRL document)

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  HARVARD BIOSCIENCE, INC.
   
   
Date: November 7, 2023 By: /s/ Jennifer Cote
    Jennifer Cote  
    Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 EX-99.1 2 exh_991.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Harvard Bioscience Announces Third Quarter 2023 Financial Results

 

·Q3 Revenues of $25.4 million
·Q3 Gross Margin of 58.1%
·Q3 GAAP operating loss of $0.9 million, adjusted operating income $1.8 million
·Continued strong operating cash flow drove debt reduction of $8.3 million through Q3

 

HOLLISTON, Mass., November 7, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter ended September 30, 2023.

  

Jim Green, Chairman and CEO said, “Overall, I’m encouraged to see solid year-over-year third quarter revenue growth in North America in a quarter that had significant headwinds in Asia. Third quarter revenues also included a net reduction of $1.3 million from discontinued products compared to the third quarter of last year. Our improved portfolio is driving significant gross margin expansion.”

 

Green continued, “We remain focused on growth through new product innovations and expanding our reach to CRO, pharma and biotech customers into industrial applications. We will be showcasing our latest innovations at next week’s Society for Neurology Conference.”

 

Financial Results Summary  Three Months Ended September 30,  Nine Months Ended September 30,
($ in millions except per share data)  2023  2022  2023  2022
Revenues  $25.4   $26.9   $84.1   $84.9 
Gross Margin   58.1%   45.2%   59.2%   53.0%
Operating (Loss) Income (GAAP)  $(0.9)  $(3.8)  $1.6   $(6.5)
Adjusted Operating Income  $1.8   $0.7   $9.8   $6.1 
Net Loss (GAAP)  $(1.2)  $(3.4)  $(1.6)  $(7.9)
Diluted Loss Per Share (GAAP)  $(0.03)  $(0.08)  $(0.04)  $(0.19)
Diluted Adjusted Earnings (Loss) Per Share  $0.01   $(0.01)  $0.11   $0.08 
Adjusted EBITDA  $2.2   $1.0   $10.9   $7.1 
Adjusted EBITDA Margin   8.9%   3.9%   13.0%   8.4%
Cash Flow provided by (used in) Operations  $4.4   $0.6   $9.7   $(1.5)
Debt, including unamortized deferred financing costs  $38.7   $49.3   $38.7   $49.3 
Net Debt (non-GAAP)  $34.0   $45.0   $34.0   $45.0 

 

 

 

Third Quarter 2023 Highlights

 

For the third quarter of fiscal 2023, the Company reported revenues of $25.4 million, a decline of 6% compared to $26.9 million in the third quarter of fiscal 2022 including a net reduction of $1.3 million from discontinued products from the third quarter of last year. Gross margin for the three months ended September 30, 2023 was 58.1% compared with 45.2% in the comparable quarter of the prior year. Gross margins in the third quarter of the prior year included the impact of a $1.3 million inventory charge related to the discontinued products.

 

Net loss for the third quarter of 2023 was ($1.2) million and included the favorable impact of a $1.2 million mark-to-market adjustment of marketable securities. This compares to net loss of ($3.4) million in the third quarter of 2022, which included the aforementioned inventory charges. Adjusted EBITDA for the third quarter of 2023 was $2.2 million, compared to adjusted EBITDA of $1.0 million in the third quarter of 2022.

 

Cash provided by operations for the third quarter of 2023 was $4.4 million compared to $0.6 million in the same period last year. Debt was reduced by $2.8 million, and net debt was reduced by $3.8 million during the third quarter of 2023.

 

Nine Months ended September 30, 2023 Highlights

 

For the nine months ended September 30, 2023, revenues were $84.1 million, compared to $84.9 million in the same period a year ago. Revenues for the nine months ended September 30, 2023 include a net reduction of $4.1 million from discontinued products compared to the same period last year. Gross margin for the nine months ended September 30, 2023 was 59.2% compared with 53.0% in the comparable period of the prior year.

 

Net loss for the nine months ended September 30, 2023 was ($1.6) million, including an unfavorable $0.4 million mark-to-market reduction of marketable securities, compared to a net loss of ($7.9) million for the comparable period of 2022. Adjusted EBITDA for the nine months ended September 30, 2023 was $10.9 million, compared to adjusted EBITDA of $7.1 million for the comparable period of 2022.

 

Cash provided by operations was $9.7 million during the nine months ended September 30, 2023 compared to $1.5 million cash used in operations in the same period last year. Debt was reduced by $8.3 million, and net debt was reduced by $9.1 million during the nine months ended September 30, 2023.

 

2023 Updated Guidance

 

With consideration of the headwinds in Asia discussed above, we now expect our fiscal 2023 revenue to be approximately flat as compared to 2022. Expected 2023 revenue includes an approximately 5 percentage point headwind from discontinued products. For the year 2023, we continue to expect gross margins of approximately 60%. We now expect adjusted EBITDA margins in the 13% to 14% range. We remain on the path to reducing our net leverage ratio to approximately 2X by the end of this year.

 

 

 

This press release includes certain financial information presented on an adjusted, or non-GAAP, basis. For additional information on the non-GAAP financial measures included in this press release, please see “Use of Non-GAAP Financial Information” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.

 

Webcast and Conference Call Details

 

In conjunction with this announcement, Harvard Bioscience will be hosting a conference call and webcast today at 8:00 a.m. Eastern Time. A presentation that will be referenced during the webcast will be posted to our Investor Relations website shortly before the webcast begins.

 

Analysts who want to join the call and ask a question must register here (https://register.vevent.com/register/BI6caa8f7af08a4f3a9dc31e44faac7cef). Once registered, you will receive the dial-in numbers and a unique PIN number.

 

Participants who want to join the audio-only webcast should go to our events and presentations on the investor website here (https://investor.harvardbioscience.com/events-and-presentations).

 

Use of Non-GAAP Financial Information

 

In this press release, we have included non-GAAP financial information, including one or more of adjusted operating income (loss), adjusted net income (loss), adjusted EBITDA, adjusted EBITDA margin, diluted adjusted earnings (loss) per share, foreign exchange adjusted revenue, net debt and net leverage ratio. We believe that this non- GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income resulting from items that we do not believe are representative of the underlying operations of the business. Items excluded include stock-based compensation, amortization of intangibles related to acquisitions, litigation settlement, restructuring and other costs, unrealized gain/loss on equity securities, income taxes, and. the tax impact of the reconciling items. Management believes that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors and financial analysts in assessing the Company’s operating performance.

 

Non-GAAP historical financial statement information included herein is accompanied by a reconciliation to the nearest corresponding GAAP measure which is included as exhibits below in this press release.

 

With respect to forward-looking measures, we provide an outlook for adjusted EBITDA margin and net leverage ratio. Many of the items that we exclude from these forward-looking measure calculations are less capable of being controlled or reliably predicted by management. These items could cause the forward-looking measures presented in our outlook statements to vary materially from our GAAP results.

 

The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies’ non-GAAP financial information.

 

 

 

About Harvard Bioscience

 

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

 

For more information, please visit our website at www.harvardbioscience.com.

 

Forward-Looking Statements

 

This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, gross margins, earnings, cash and debt position, growth and the introduction of new products, and the strength of the Company’s market position and business model. Forward-looking statements are not guarantees of future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.

 

 

Investor Inquiries:

 

Harvard Bioscience, Inc.

Investor Relations investors@harvardbioscience.com

(508) 893-3120

 

 

 

 

 

     
  HARVARD BIOSCIENCE, INC.  
  Consolidated Statements of Operations  
  (unaudited, in thousands, except per share data)  
     
     Three Months Ended  Nine Months Ended  
     September 30, 2023  September 30, 2022  September 30, 2023  September 30, 2022  
                 
  Revenues  $25,363   $26,922   $84,097   $84,908   
  Cost of revenues   10,636    14,750    34,351    39,922   
  Gross profit   14,727    12,172    49,746    44,986   
                         
  Operating expenses:                      
  Sales and marketing expenses   5,732    5,819    17,888    19,093   
  General and administrative expenses   5,807    6,324    17,494    18,630   
  Research and development expenses   2,760    2,763    8,614    9,480   
  Amortization of intangible assets   1,361    1,572    4,138    4,492   
  Litigation settlement   —      (544)   —      (233)  
  Total operating expenses   15,660    15,934    48,134    51,462   
                         
  Operating (loss) income   (933)   (3,762)   1,612    (6,476)  
                         
  Other income (expense):                      
  Unrealized gain (loss) on equity securities   1,208    —      (373)   —     
  Interest expense   (882)   (749)   (2,797)   (1,648)  
  Other income (expense), net   45    (179)   105    (163)  
  Total other income (expense)   371    (928)   (3,065)   (1,811)  
  Loss before income taxes   (562)   (4,690)   (1,453)   (8,287)  
  Income tax expense (benefit)   677    (1,285)   144    (437)  
  Net loss  $(1,239)  $(3,405)  $(1,597)  $(7,850)  
                         
  Loss per common share:                      
  Basic and diluted  $(0.03)  $(0.08)  $(0.04)  $(0.19)  
                         
  Weighted-average common shares:                      
  Basic and diluted   42,688    41,637    42,345    41,353   
                         

 

 

 

 

     
  HARVARD BIOSCIENCE, INC.  
  Condensed Consolidated Balance Sheets  
  (unaudited, in thousands)  
           
      September 30, 2023    December 31, 2022   
  Assets            
  Cash and cash equivalents  $5,340   $4,508   
  Accounts receivable, net   14,983    16,705   
  Inventories   25,818    26,439   
  Other current assets   4,345    3,472   
  Total current assets   50,486    51,124   
  Property, plant and equipment   3,358    3,366   
  Goodwill and other intangibles   73,317    77,274   
  Other long-term assets   12,574    13,596   
  Total assets  $139,735   $145,360   
               
  Liabilities and Stockholders' Equity            
  Current portion, long-term debt  $3,470   $3,811   
  Other current liabilities   20,735    19,438   
  Total current liabilities   24,205    23,249   
  Long-term debt, net   35,273    43,013   
  Other long-term liabilities   5,971    6,878   
  Stockholders’ equity   74,286    72,220   
  Total liabilities and stockholders’ equity  $139,735   $145,360   
               

 

 

 

 

 

     
  HARVARD BIOSCIENCE, INC.  
  Condensed Consolidated Statements of Cash Flows  
  (unaudited, in thousands)  
                 
     Three Months Ended  Nine Months Ended  
     September 30, 2023  September 30, 2022  September 30, 2023  September 30, 2022  
  Cash flows from operating activities:                      
  Net loss  $(1,239)  $(3,405)  $(1,597)  $(7,850)  
  Adjustments to operating cash flows   2,010    1,945    9,111    5,165   
  Changes in operating assets and liabilities   3,590    2,109    2,211    1,158   
  Net cash provided by (used in) operating activities   4,361    649    9,725    (1,527)  
                         
  Cash flows from investing activities:                      
  Additions to property, plant and equipment   (217)   (442)   (958)   (1,355)  
  Acquisition of intangible assets   (184)   —      (292)   —     
  Proceeds from sale of product line   —      —      512    —     
  Net cash used in investing activities   (401)   (442)   (738)   (1,355)  
                         
  Cash flows from financing activities:                      
  Borrowing from revolving line of credit   1,000    2,500    3,500    7,800   
  Repayment of revolving line of credit   (3,000)   (1,050)   (8,450)   (4,650)  
  Repayment of term debt   (750)   (750)   (3,341)   (2,436)  
  Proceeds from exercise of employee stock options and purchases   —      64    724    346   
  Taxes paid related to net share settlement of equity awards   —      (387)   (451)   (1,167)  
  Net cash used in (provided by) financing activities   (2,750)   377    (8,018)   (107)  
                         
  Effect of exchange rate changes on cash   (211)   337    (137)   312   
  Increase (decrease) in cash and cash equivalents   999    921    832    (2,677)  
  Cash and cash equivalents at the beginning of period   4,341    4,223    4,508    7,821   
  Cash and cash equivalents at the end of period  $5,340   $5,144   $5,340   $5,144   
                         

 

 

 

 

 

 

     
  HARVARD BIOSCIENCE, INC.  
  Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)  
  (in thousands, except per share data)  
     Three Months Ended  Nine Months Ended  
     September 30, 2023  September 30, 2022  September 30, 2023  September 30, 2022  
                 
                         
  GAAP operating (loss) income  $(933)  $(3,762)  $1,612   $(6,476)  
  Stock-based compensation   1,363    1,139    3,618    3,401   
  Acquired asset amortization   1,369    1,596    4,167    4,588   
  Restructuring & other   42    2,273    450    4,924   
  Settlement   -    (544)   -    (311)  
  Adjusted operating income  $1,841   $702   $9,847   $6,126   
                         
  Operating margin   -3.7%   -14.0%   1.9%   -7.6%  
  Adjusted operating margin   7.3%   2.6%   11.7%   7.2%  
                         
                         
                         
  GAAP net loss  $(1,239)  $(3,405)  $(1,597)  $(7,850)  
  Stock-based compensation   1,363    1,139    3,618    3,401   
  Acquired asset amortization   1,369    1,596    4,167    4,588   
  Restructuring & other   42    2,193    46    4,844   
  Settlement   -    (544)   -    (311)  
  Unrealized (gain) loss on equity securities   (1,208)   -    374    -   
  Income taxes   196    (1,244)   (1,919)   (1,409)  
  Adjusted net income (loss)   523    (265)   4,689    3,263   
  Depreciation   405    341    1,054    1,024   
  Interest and other expense, net   837    1,006    3,095    1,889   
  Adjusted income taxes (1)   481    (41)   2,063    972   
  Adjusted EBITDA  $2,246   $1,041   $10,901   $7,148   
                         
  Adjusted EBITDA margin   8.9%   3.9%   13.0%   8.4%  
                         
                         
  Diluted loss per share (GAAP)  $(0.03)  $(0.08)  $(0.04)  $(0.19)  
                         
  Diluted adjusted earnings (loss) per share  $0.01   $(0.01)  $0.11   $0.08   
  Weighted-average common shares:                      
  Diluted GAAP   42,688    41,637    42,345    41,353   
                         
  Diluted Adjusted   44,563    41,637    44,195    42,665   
                         
                         
      September 30, 2023    June 30, 2023    December 31, 2022    September 30, 2022   
  Debt, including unamortized deferred financing costs  $38,743   $41,423   $46,824   $49,254   
  Unamortized deferred financing costs   630    700    840    910   
  Cash and cash equivalents   (5,340)   (4,324)   (4,508)   (5,144)  
  Net debt  $34,033   $37,799   $43,156   $45,020   
                         
                         
  (1) Adjusted income taxes includes the tax effect of adjusting for the reconciling items using the tax rates in the jurisdictions in which the reconciling items arise.   
                         
  Net leverage ratio is defined herein as net debt divided by our trailing twelve months adjusted EBITDA.             
                         

 

 

 

 

 

 GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg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end EX-101.SCH 4 hbio-20231107.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 hbio-20231107_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 hbio-20231107_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 07, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 07, 2023
Entity File Number 001-33957
Entity Registrant Name HARVARD BIOSCIENCE, INC.
Entity Central Index Key 0001123494
Entity Tax Identification Number 04-3306140
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 84 October Hill Road
Entity Address, City or Town Holliston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01746
City Area Code (508)
Local Phone Number 893-8999
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol HBIO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 f8k_110323_htm.xml IDEA: XBRL DOCUMENT 0001123494 2023-11-07 2023-11-07 iso4217:USD shares iso4217:USD shares 0001123494 false 8-K 2023-11-07 HARVARD BIOSCIENCE, INC. DE 001-33957 04-3306140 84 October Hill Road Holliston MA 01746 (508) 893-8999 false false false false Common Stock, $0.01 par value HBIO NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ M "(" / " 500 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 M " 2.&=7)!Z;HJT #X 0 &@ @ &T$0 >&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " 2.&=799!YDAD! #/ M P $P @ &9$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 "0 ) #X" #C$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_110323.htm hbio-20231107.xsd hbio-20231107_lab.xml hbio-20231107_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f8k_110323.htm": { "nsprefix": "HBIO", "nsuri": "http://globenewswire.com/20231107", "dts": { "inline": { "local": [ "f8k_110323.htm" ] }, "schema": { "local": [ "hbio-20231107.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "hbio-20231107_lab.xml" ] }, "presentationLink": { "local": [ "hbio-20231107_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://globenewswire.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_110323.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_110323.htm", "first": true, "unique": true } } }, "tag": { "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001171843-23-006794-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-23-006794-xbrl.zip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